FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis

PHASE3CompletedINTERVENTIONAL
Enrollment

344

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

August 31, 2020

Study Completion Date

October 31, 2020

Conditions
Tuberculosis, MDR
Interventions
DRUG

FS-1

FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.

DRUG

Placebo

Placebo without any active pharmaceutical ingredients

Trial Locations (6)

071400

Semey Medical University, Semey

030019

West Kazakhstan Marat Ospanov Medical University, Aktobe

National Center of Phthisiatry, Bishkek

050010

National scientific center of phthisiopulmonology Ministry of health of the Republic of Kazakhstan, Almaty

050030

Center of Phthisiopulmonology of the Public Health Administration of Almaty, Almaty

Unknown

Karaganda Medical University, Karaganda

All Listed Sponsors
collaborator

Phthisiopulmonology Center of Almaty, Kazakhstan

UNKNOWN

collaborator

National Scientific Center of Phthisiopulmonology, Kazakhstan

UNKNOWN

collaborator

Karaganda Medical University

OTHER

collaborator

West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

UNKNOWN

collaborator

Semey State Medical University

OTHER

collaborator

National Center of Phthisiatry, Bishkek, Kyrgyzstan

OTHER

collaborator

Invivo laboratory, Kazakhstan

UNKNOWN

lead

Scientific Center for Anti-infectious Drugs, Kazakhstan

INDUSTRY

NCT02607449 - FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis | Biotech Hunter | Biotech Hunter